Details of the Drug

General Information of Drug (ID: DMB39LO)

Drug Name
Metolazone
Synonyms
Diulo; Metalazone; Metalozone; Metenix; Metolazona; Metolazonum; Microx; Mykrox; Oldren; Xuret; Zaroxolyn; Metolazona [INN-Spanish]; Metolazonum [INN-Latin]; Mykrox (TN); SR 720-22; Zaroxolyn (TN); SR-720-22; Metolazone (JAN/USP/INN); Metolazone [USAN:BAN:INN:JAN]; Mykrox, Zaroxolyn, Diulo, Metolazone; 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide; 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide; 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
Indication
Disease Entry ICD 11 Status REF
Edema MG29 Approved [1]
Hypertension BA00-BA04 Approved [1]
Therapeutic Class
Antihypertensive Agents
Affected Organisms
Humans and other mammals
ATC Code
C03BA08: Metolazone
C03BA: Sulfonamides, plain
C03B: LOW-CEILING DIURETICS, EXCL. THIAZIDES
C03: DIURETICS
C: CARDIOVASCULAR SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 365.8
Logarithm of the Partition Coefficient (xlogp) 4.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Bioavailability
65% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 1.4 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 14 hours [4]
Metabolism
The drug is metabolized via the glomerular filtration and active tubular secretion []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.781 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.6 L/kg [4]
Chemical Identifiers
Formula
C16H16ClN3O3S
IUPAC Name
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide
Canonical SMILES
CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl
InChI
InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
InChIKey
AQCHWTWZEMGIFD-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4170
ChEBI ID
CHEMBL878
CAS Number
17560-51-9
UNII
TZ7V40X7VX
DrugBank ID
DB00524
TTD ID
D01WLC
VARIDT ID
DR01032
ACDINA ID
D00423
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 12 member 3 (SLC12A3) TTP362L S12A3_HUMAN Blocker [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Thiazide-sensitive sodium-chloride cotransporter (SLC12A3) DT6MDC9 S12A3_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
HLA class II histocompatibility antigen, DQ beta 2 chain (HLA-DQB2) OTZYAIBF DQB2_HUMAN Gene/Protein Processing [8]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Metolazone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Scopolamine DMOM8AL Minor Altered absorption of Metolazone due to GI dynamics variation caused by Scopolamine. Addictive disorder [6C50-6C5Z] [10]
Dronedarone DMA8FS5 Major Increased risk of ventricular arrhythmias by the combination of Metolazone and Dronedarone. Angina pectoris [BA40] [11]
Linezolid DMGFPU2 Moderate Additive hypotensive effects by the combination of Metolazone and Linezolid. Bacterial infection [1A00-1C4Z] [12]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Metolazone and Rabeprazole. Bacterial infection [1A00-1C4Z] [13]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Metolazone and Cariprazine. Bipolar disorder [6A60] [14]
Phenylbutazone DMAYL0T Moderate Antagonize the effect of Metolazone when combined with Phenylbutazone. Chronic pain [MG30] [15]
Ketoprofen DMRKXPT Moderate Antagonize the effect of Metolazone when combined with Ketoprofen. Chronic pain [MG30] [15]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Metolazone and Levomilnacipran. Chronic pain [MG30] [16]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Metolazone and Olopatadine. Conjunctiva disorder [9A60] [17]
Sertraline DM0FB1J Moderate Increased risk of hyponatremia by the combination of Metolazone and Sertraline. Depression [6A70-6A7Z] [16]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Metolazone and Vilazodone. Depression [6A70-6A7Z] [16]
Paroxetine DM5PVQE Moderate Increased risk of hyponatremia by the combination of Metolazone and Paroxetine. Depression [6A70-6A7Z] [16]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Metolazone and Selegiline. Depression [6A70-6A7Z] [12]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Metolazone and Vortioxetine. Depression [6A70-6A7Z] [16]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Metolazone and Isocarboxazid. Depression [6A70-6A7Z] [12]
Milnacipran DMBFE74 Moderate Increased risk of hyponatremia by the combination of Metolazone and Milnacipran. Depression [6A70-6A7Z] [16]
Escitalopram DMFK9HG Moderate Increased risk of hyponatremia by the combination of Metolazone and Escitalopram. Depression [6A70-6A7Z] [16]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Metolazone and Tranylcypromine. Depression [6A70-6A7Z] [12]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Metolazone and Desvenlafaxine. Depression [6A70-6A7Z] [16]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Metolazone and OPC-34712. Depression [6A70-6A7Z] [14]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Metolazone and Phenelzine. Depression [6A70-6A7Z] [12]
Mepenzolate DM8YU2F Minor Altered absorption of Metolazone due to GI dynamics variation caused by Mepenzolate. Digestive system disease [DE2Z] [10]
Oxybutynine DMJPBAX Minor Altered absorption of Metolazone due to GI dynamics variation caused by Oxybutynine. Discovery agent [N.A.] [10]
Carbamazepine DMZOLBI Moderate Increased risk of hyponatremia by the combination of Metolazone and Carbamazepine. Epilepsy/seizure [8A61-8A6Z] [18]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Metolazone and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [19]
Ethacrynic acid DM60QMR Moderate Increased risk of fluid/electrolyte loss by the combination of Metolazone and Ethacrynic acid. Essential hypertension [BA00] [20]
Nadolol DMW6GVL Moderate Increased risk of hyperglycemia by the combination of Metolazone and Nadolol. Essential hypertension [BA00] [21]
Mefenamic acid DMK7HFI Moderate Antagonize the effect of Metolazone when combined with Mefenamic acid. Female pelvic pain [GA34] [15]
Solifenacin DMG592Q Minor Altered absorption of Metolazone due to GI dynamics variation caused by Solifenacin. Functional bladder disorder [GC50] [10]
Tolterodine DMSHPW8 Minor Altered absorption of Metolazone due to GI dynamics variation caused by Tolterodine. Functional bladder disorder [GC50] [10]
Propantheline DM2EN6G Minor Altered absorption of Metolazone due to GI dynamics variation caused by Propantheline. Gastric ulcer [DA60] [10]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Metolazone and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [13]
Cisapride DMY7PED Major Increased risk of ventricular arrhythmias by the combination of Metolazone and Cisapride. Gastro-oesophageal reflux disease [DA22] [22]
Metipranolol DMJMVKI Moderate Increased risk of hypertriglyceridemia by the combination of Metolazone and Metipranolol. Glaucoma [9C61] [21]
Levobunolol DMTNFCQ Moderate Increased risk of hypertriglyceridemia by the combination of Metolazone and Levobunolol. Glaucoma [9C61] [21]
Carvedilol DMHTEAO Moderate Increased risk of hyperglycemia by the combination of Metolazone and Carvedilol. Heart failure [BD10-BD1Z] [21]
Furosemide DMMQ8ZG Moderate Increased risk of fluid/electrolyte loss by the combination of Metolazone and Furosemide. Heart failure [BD10-BD1Z] [20]
Bumetanide DMRV7H0 Moderate Increased risk of fluid/electrolyte loss by the combination of Metolazone and Bumetanide. Heart failure [BD10-BD1Z] [20]
Digitoxin DMWVIGP Moderate Increased risk of hypokalemia by the combination of Metolazone and Digitoxin. Heart failure [BD10-BD1Z] [23]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Metolazone and Procarbazine. Hodgkin lymphoma [2B30] [12]
Acebutolol DM0TI4U Moderate Increased risk of hyperglycemia by the combination of Metolazone and Acebutolol. Hypertension [BA00-BA04] [21]
Moexipril DM26E4B Moderate Additive hypotensive effects by the combination of Metolazone and Moexipril. Hypertension [BA00-BA04] [24]
Bisoprolol DM3UZ95 Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Bisoprolol. Hypertension [BA00-BA04] [21]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Metolazone and Captopril. Hypertension [BA00-BA04] [24]
Nebivolol DM7F1PA Moderate Increased risk of hyperglycemia by the combination of Metolazone and Nebivolol. Hypertension [BA00-BA04] [21]
Pindolol DMD2NV7 Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Pindolol. Hypertension [BA00-BA04] [21]
Benazepril DMH1M9B Moderate Additive hypotensive effects by the combination of Metolazone and Benazepril. Hypertension [BA00-BA04] [24]
Labetalol DMK8U72 Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Labetalol. Hypertension [BA00-BA04] [21]
Enalapril DMNFUZR Moderate Additive hypotensive effects by the combination of Metolazone and Enalapril. Hypertension [BA00-BA04] [24]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Metolazone and Perindopril. Hypertension [BA00-BA04] [24]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Metolazone and Quinapril. Hypertension [BA00-BA04] [24]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Metolazone and Lisinopril. Hypertension [BA00-BA04] [24]
Belladonna DM2RBWK Minor Altered absorption of Metolazone due to GI dynamics variation caused by Belladonna. Infectious gastroenteritis/colitis [1A40] [10]
Meclofenamic acid DM05FXR Moderate Antagonize the effect of Metolazone when combined with Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [15]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Metolazone and Propiomazine. Insomnia [7A00-7A0Z] [14]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Metolazone and ITI-007. Insomnia [7A00-7A0Z] [14]
Clidinium DMUMQZ0 Minor Altered absorption of Metolazone due to GI dynamics variation caused by Clidinium. Irritable bowel syndrome [DD91] [10]
Dicyclomine DMZSDGX Minor Altered absorption of Metolazone due to GI dynamics variation caused by Dicyclomine. Irritable bowel syndrome [DD91] [10]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Metolazone and Porfimer Sodium. Lung cancer [2C25] [25]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Metolazone and Arsenic trioxide. Mature B-cell lymphoma [2A85] [26]
Propranolol DM79NTF Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Propranolol. Migraine [8A80] [21]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Metolazone and Ozanimod. Multiple sclerosis [8A40] [12]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Metolazone and Methoxsalen. Mycosis fungoides [2B01] [27]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Metolazone and Promethazine. Nausea/vomiting [MD90] [14]
Sibutramine DMFJTDI Moderate Increased risk of hyponatremia by the combination of Metolazone and Sibutramine. Obesity [5B80-5B81] [16]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Metolazone and Levomethadyl Acetate. Opioid use disorder [6C43] [28]
Rofecoxib DM3P5DA Moderate Antagonize the effect of Metolazone when combined with Rofecoxib. Osteoarthritis [FA00-FA05] [15]
Valdecoxib DMAY7H4 Moderate Antagonize the effect of Metolazone when combined with Valdecoxib. Osteoarthritis [FA00-FA05] [15]
Diclofenac DMPIHLS Moderate Antagonize the effect of Metolazone when combined with Diclofenac. Osteoarthritis [FA00-FA05] [15]
Naproxen DMZ5RGV Moderate Antagonize the effect of Metolazone when combined with Naproxen. Osteoarthritis [FA00-FA05] [15]
Etodolac DM6WJO9 Moderate Antagonize the effect of Metolazone when combined with Etodolac. Pain [MG30-MG3Z] [15]
Diflunisal DM7EN8I Moderate Antagonize the effect of Metolazone when combined with Diflunisal. Pain [MG30-MG3Z] [15]
Ibuprofen DM8VCBE Moderate Antagonize the effect of Metolazone when combined with Ibuprofen. Pain [MG30-MG3Z] [15]
Flavoxate DMKV4NL Minor Altered absorption of Metolazone due to GI dynamics variation caused by Flavoxate. Pain [MG30-MG3Z] [10]
Piroxicam DMTK234 Moderate Antagonize the effect of Metolazone when combined with Piroxicam. Pain [MG30-MG3Z] [15]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Metolazone and Safinamide. Parkinsonism [8A00] [12]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Metolazone and Rasagiline. Parkinsonism [8A00] [12]
Biperiden DME78OA Minor Altered absorption of Metolazone due to GI dynamics variation caused by Biperiden. Parkinsonism [8A00] [10]
Methylscopolamine DM5VWOB Minor Altered absorption of Metolazone due to GI dynamics variation caused by Methylscopolamine. Peptic ulcer [DA61] [10]
Esomeprazole DM7BN0X Moderate Increased risk of hypomagnesemia by the combination of Metolazone and Esomeprazole. Peptic ulcer [DA61] [13]
Bromfenac DMKB79O Moderate Antagonize the effect of Metolazone when combined with Bromfenac. Postoperative inflammation [1A00-CA43] [15]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Metolazone and Levomepromazine. Psychotic disorder [6A20-6A25] [14]
Fluphenazine DMIT8LX Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Fluphenazine. Psychotic disorder [6A20-6A25] [27]
Meloxicam DM2AR7L Moderate Antagonize the effect of Metolazone when combined with Meloxicam. Rheumatoid arthritis [FA20] [15]
Sulindac DM2QHZU Moderate Antagonize the effect of Metolazone when combined with Sulindac. Rheumatoid arthritis [FA20] [15]
Oxaprozin DM9UB0P Moderate Antagonize the effect of Metolazone when combined with Oxaprozin. Rheumatoid arthritis [FA20] [15]
Flurbiprofen DMGN4BY Moderate Antagonize the effect of Metolazone when combined with Flurbiprofen. Rheumatoid arthritis [FA20] [15]
Fenoprofen DML5VQ0 Moderate Antagonize the effect of Metolazone when combined with Fenoprofen. Rheumatoid arthritis [FA20] [15]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Metolazone and Quetiapine. Schizophrenia [6A20] [14]
Mesoridazine DM2ZGAN Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Mesoridazine. Schizophrenia [6A20] [27]
Thioridazine DM35M8J Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Thioridazine. Schizophrenia [6A20] [27]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Metolazone and Aripiprazole. Schizophrenia [6A20] [14]
Iloperidone DM6AUFY Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Iloperidone. Schizophrenia [6A20] [27]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Paliperidone. Schizophrenia [6A20] [27]
Perphenazine DMA4MRX Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Perphenazine. Schizophrenia [6A20] [27]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Metolazone and Molindone. Schizophrenia [6A20] [14]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Metolazone and Thiothixene. Schizophrenia [6A20] [14]
Trifluoperazine DMKBYWI Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Trifluoperazine. Schizophrenia [6A20] [27]
Risperidone DMN6DXL Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Risperidone. Schizophrenia [6A20] [27]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Metolazone and Amisulpride. Schizophrenia [6A20] [27]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Metolazone and Asenapine. Schizophrenia [6A20] [14]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Metolazone and Pimozide. Schizophrenia [6A20] [29]
Atropine DMEN6X7 Minor Altered absorption of Metolazone due to GI dynamics variation caused by Atropine. Unspecific substance harmful effect [NE6Z] [10]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Metolazone and Methdilazine. Vasomotor/allergic rhinitis [CA08] [14]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Metolazone and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [30]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Metolazone and Amiodarone. Ventricular tachyarrhythmia [BC71] [31]
⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 30 E00456 3000709 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sunset yellow FCF E00255 17730 Colorant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Metolazone 10 mg tablet 10 mg Oral Tablet Oral
Metolazone 2.5 mg tablet 2.5 mg Oral Tablet Oral
Metolazone 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4838).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22.
7 Inhibition of binding of [3H]metolazone to rat kidney membrane by stilbene disulfonates. Biochem Pharmacol. 1991 Jun 1;41(11):1745-50.
8 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
9 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
10 Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798]
11 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
12 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
13 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
14 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
15 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
16 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
17 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
18 Yassa R, Nastase C, Camille Y, Henderson M, Belzile L, Beland F "Carbamazepine, diuretics, and hyponatremia: a possible interaction." J Clin Psychiatry 48 (1987): 281-3. [PMID: 3597330]
19 Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
20 Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
21 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
22 Product Information. Propulsid (cisapride). Janssen Pharmaceutica, Titusville, NJ.
23 Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
24 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
25 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
26 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
27 Cerner Multum, Inc. "Australian Product Information.".
28 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
29 Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
30 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
31 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]